JP2020510042A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510042A5
JP2020510042A5 JP2019549396A JP2019549396A JP2020510042A5 JP 2020510042 A5 JP2020510042 A5 JP 2020510042A5 JP 2019549396 A JP2019549396 A JP 2019549396A JP 2019549396 A JP2019549396 A JP 2019549396A JP 2020510042 A5 JP2020510042 A5 JP 2020510042A5
Authority
JP
Japan
Prior art keywords
days
approximately
affected area
approx
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019549396A
Other languages
English (en)
Japanese (ja)
Other versions
JP7502863B2 (ja
JP2020510042A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021929 external-priority patent/WO2018165647A1/en
Publication of JP2020510042A publication Critical patent/JP2020510042A/ja
Publication of JP2020510042A5 publication Critical patent/JP2020510042A5/ja
Priority to JP2022180723A priority Critical patent/JP2023015269A/ja
Application granted granted Critical
Publication of JP7502863B2 publication Critical patent/JP7502863B2/ja
Priority to JP2024207319A priority patent/JP2025029010A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019549396A 2017-03-10 2018-03-12 光線角化症を治療および/または予防する方法 Active JP7502863B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022180723A JP2023015269A (ja) 2017-03-10 2022-11-11 光線角化症を治療および/または予防する方法
JP2024207319A JP2025029010A (ja) 2017-03-10 2024-11-28 光線角化症を治療および/または予防する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
US62/469,889 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022180723A Division JP2023015269A (ja) 2017-03-10 2022-11-11 光線角化症を治療および/または予防する方法

Publications (3)

Publication Number Publication Date
JP2020510042A JP2020510042A (ja) 2020-04-02
JP2020510042A5 true JP2020510042A5 (enExample) 2021-04-08
JP7502863B2 JP7502863B2 (ja) 2024-06-19

Family

ID=63446658

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549396A Active JP7502863B2 (ja) 2017-03-10 2018-03-12 光線角化症を治療および/または予防する方法
JP2022180723A Pending JP2023015269A (ja) 2017-03-10 2022-11-11 光線角化症を治療および/または予防する方法
JP2024207319A Pending JP2025029010A (ja) 2017-03-10 2024-11-28 光線角化症を治療および/または予防する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022180723A Pending JP2023015269A (ja) 2017-03-10 2022-11-11 光線角化症を治療および/または予防する方法
JP2024207319A Pending JP2025029010A (ja) 2017-03-10 2024-11-28 光線角化症を治療および/または予防する方法

Country Status (13)

Country Link
US (3) US10617693B2 (enExample)
EP (2) EP3592355B1 (enExample)
JP (3) JP7502863B2 (enExample)
KR (2) KR20190141661A (enExample)
CN (1) CN110891575A (enExample)
AU (2) AU2018231144B2 (enExample)
BR (1) BR112019018687A2 (enExample)
CA (1) CA3055938A1 (enExample)
IL (1) IL269182B2 (enExample)
MX (2) MX387658B (enExample)
TW (1) TWI841523B (enExample)
WO (1) WO2018165647A1 (enExample)
ZA (1) ZA202100106B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica
FI3679016T3 (fi) 2017-09-07 2025-12-12 Atnx Spv Llc 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja
CA3092939C (en) * 2018-03-07 2024-10-08 Atnx Spv, Llc USE OF THE COMBINATION OF KX01 AND VITAMIN D TO TREAT HYPERPROLIFERATIVE SKIN DISORDERS
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技(广州)有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
DK1836169T5 (da) 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
RS58566B1 (sr) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corp Formulacije imikuimoda niže dozne jačine i kratkih režima doziranja za lečenje aktinične keratoze
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Similar Documents

Publication Publication Date Title
JP2020510042A5 (enExample)
CN108853312B (zh) 聚桂醇外用凝胶及其制备方法
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
JP4243353B2 (ja) 皮膚疾患の治療に用いる共役リノール酸の亜鉛塩
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2012525358A5 (enExample)
JP2016505050A5 (enExample)
WO2013182998A2 (en) Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes
Cutler et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus
Bromham et al. Updating the clinical experience in endometriosis–the European perspective
WO2016181355A1 (en) Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity
CN103142794B (zh) 拔毒祛疮膏
JPH08500343A (ja) セシウムイオンを用いた治療方法
Š? ÁVA et al. Salazopyrin in the treatment of scleroderma
JP3830963B2 (ja) 乾癬治療
WO2023019095A3 (en) Momelotinib combination therapy
EP2712613B1 (en) Vitamin K1 and uses thereof
TW200418447A (en) New method for treating urinary disorders
US20130045287A1 (en) Treatment for Concussion using Gallium Compounds
CN114452292B (zh) 白头翁皂苷b4在制备皮肤护理品中的应用
CN114469969B (zh) 白头翁皂苷b5在制备皮肤护理品中的应用
JPWO2020247706A5 (enExample)
RU2313327C1 (ru) Способ лечения угревой болезни
Kim et al. Combination of Calcipotriene Foam, 0.005% and Tazarotene Foam, 0.1% in the Treatment of Plaque Psoriasis of the Scalp and Body: A Case Report
EP2849742A1 (en) Method of topically treating actinic keratosis with ingenol mebutate cycle therapy